Business
Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses
- Eight abstracts accepted, including three oral presentations - Maralixibat data highlighting predictors of event-free survival in patients with Alagille
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- Eight abstracts accepted, including three oral presentations\n\n- Maralixibat data highlighting predictors of event-free survival in patients with Alagille syndrome nominated for prestigious Alex Mowat Prize for best oral presentation in hepatology\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\n\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) will present data at the upcoming International Liver Congress™ of the European Association for the Study of the Liver (EASL) and the 54th Annual European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting (ESPGHAN), taking place in London and Copenhagen, respectively. The Company will present data from its LIVMARLI® (maralixibat) clinical studies and will unveil a multi-national survey of patient-reported outcomes data assessing pruritus and overall disease burden in adults with primary sclerosing cholangitis.\n\nMirum will also host a scientific symposium during each meeting:\n\n\nEASL: “Patient, caregiver, and physician: Understanding perspectives in adult and pediatric cholestasis”\n\n\nThursday, June 23, 2022 from 6:30-8:00 p.m. BST\n\n\n\n\nESPGHAN: “Cholestatic Disease in Children: From Diagnosis to Patient Management”\n\n\nThursday, June 23, 2022 from 6:15-7:15 p.m. CEST\n\n\n\n\n**ESPGHAN: June 22-25, 2022, Copenhagen, Denmark**\n\nAll abstracts are available via the Journal of Paediatric Gastroenterology and Nutrition and the page number for each abstract is enclosed with the title below.\n\nOral presentations\n\nH-O-008: Maralixibat treatment response is associated with improved health-related quality of life in patients with bile salt export pump (BSEP) deficiency (pg. 650)\nOral presentation: June 23, 2022 at 5:00 p.m. CEST\nPresenter: Dr. Douglas Mogul (on behalf of Dr. Kathy Loomes)\n\nH-O-012: Predictors of 6-year event-free survival in patients with Alagille syndrome treated with maralixibat, an IBAT inhibitor (pg. 658)\nOral presentation: June 24, 2022 at 8:45 a.m. CEST\n**Nominated for the Alex Mowat Prize for Best Oral Presentation in Hepatology**\nPresenter: Dr. Ronald Sokol\n\nH-O-018: Maralixibat-treated patients with Alagille syndrome (ALGS) demonstrate improved event-free survival in a natural history comparison with patients from the GALA database: application of real-world evidence analytics (pg. 670)\nOral presentation: June 24, 2022 a...